Fluoxetine/Bupropion Suicide Attempters Major Depressive

氟西汀/安非他酮自杀未遂者重度抑郁症

• 批准号: 7024808
• 负责人: Michael F Grunebaum
• 金额: $ 17.67万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-06 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7024808
• 关键词: aggression; amine oxidase (flavin); antidepressants; attention; behavioral /social science research tag; behavioral genetics; body physical activity; bupropion; clinical research; clinical trials; drug screening /evaluation; fluoxetine; genetic markers; genetic polymorphism; human subject; human therapy evaluation; impulsive behavior; job performance; major depression; mental disorder chemotherapy; neuropsychological tests; patient oriented research; pharmacogenetics; psychomotor function; serotonin transporter; suicide

DESCRIPTION (provided by applicant): Major depressive disorder (MOD) is a common and serious psychiatric illness. It is among the leading causes of disability and is the psychiatric disorder most frequently associated with suicide. Yet the treatment of MOD with antidepressant medication remains largely a trial-and-error process and little empirical evidence exists to guide treatment when suicide prevention is a priority. The purpose of this patient-oriented K-award is to develop and execute a program of research that will investigate clinical, neuropsychological and genetic predictors of response to different types of antidepressant medications in a high-risk sample of persons with MOD and a history of suicide attempt. Changes in clinical and neuropsychological components of depression and the diathesis for suicide will be compared during treatment with a serotonergic versus a non- serotonergic antidepressant. We will also determine whether functional polymorphisms in genes related to depression or the diathesis for suicide predict therapeutic effects of these antidepressants on mood or components of the diathesis for suicide. The principal investigator will carry out this program of research career development under the strong mentorship of Dr. J. John Mann (for training in the clinical neurobiology of depression and suicide). Active consultation and additional mentorship will come from Dr. A. John Rush (for training in antidepressant clinical trial design and execution), Dr. Bruce G. Pollock (for training in antidepressant pharmacogenetics), Dr. Joseph D. Terwilliger (for training in genetic epidemiology), Dr. John Keilp (for training in use of neuropsychological tests) and from Dr. Eva Petkova (for training in statistical analytic methods). This patient-oriented career development award will provide the principal investigator with the further experience and skills necessary to integrate clinical and scientific expertise in the field of depression and suicide clinical trials research. The long-term goal of this award is for the candidate to become an expert and independent clinical researcher on the treatment of depression with a special focus on suicide prevention.

描述（由申请人提供）： 重度抑郁症（MOD）是一种常见且严重的精神疾病。它是导致残疾的主要原因之一，也是最常与自杀相关的精神疾病。然而，抗抑郁药物治疗 MOD 在很大程度上仍然是一个反复试验的过程，当优先考虑预防自杀时，几乎没有经验证据可以指导治疗。这项以患者为导向的 K 奖的目的是制定和执行一项研究计划，该计划将在患有 MOD 且有自杀未遂史的高风险样本中调查对不同类型抗抑郁药物反应的临床、神经心理学和遗传预测因素。将比较血清素能抗抑郁药与非血清素能抗抑郁药治疗期间抑郁症的临床和神经心理学成分的变化以及自杀倾向。我们还将确定与抑郁症或自杀素质相关的基因的功能多态性是否可以预测这些抗抑郁药对情绪或自杀素质组成部分的治疗效果。首席研究员将在 J. John Mann 博士（抑郁症和自杀的临床神经生物学培训）的大力指导下开展这一研究职业发展计划。 A. John Rush 博士（抗抑郁药临床试验设计和执行培训）、Bruce G. Pollock 博士（抗抑郁药物遗传学培训）、Joseph D. Terwilliger 博士（遗传流行病学培训）、John Keilp 博士（神经心理学测试使用培训）和 Eva Petkova 博士（统计分析培训）将提供积极咨询和额外指导。 方法）。这一以患者为导向的职业发展奖将为主要研究者提供整合抑郁症和自杀临床试验研究领域的临床和科学专业知识所需的进一步经验和技能。该奖项的长期目标是让候选人成为抑郁症治疗方面的专家和独立临床研究员，特别关注自杀预防。